You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀首予榮昌生物-B(09995.HK)「中性」評級 目標價108元
阿思達克 04-12 09:39
瑞銀發表研究報告,指出榮昌生物(09995.HK)擁有強大的內部研發能力,產品線有超過10款新藥在研發中,覆蓋自身免疫、腫瘤學及眼科疾病等領域,不少產品今年將進入商業化階段,首予「中性」評級。

報告指出,榮昌生物的核心產品泰它西普(RC18)已於3月在中國推出,而另一款胃癌新藥Disitamab Vedotin(RC48)則預期快將獲批。該行指出,兩款產品正在中國及美國就適應症進行6個註冊實驗,預期隨著商業團隊和製造設施的擴充,期望2024年可達到收支平衡。

瑞銀指,泰它西普是國內首個批准用於SLE治療的生物製劑,目前在美國處於3期試驗,料成為公司主要增長動力,預期至2023年峰值銷售額可達到86億元人民幣;而RC48預期至2030年峰值銷售額可達11億元人民幣。

瑞銀基於2030年總峰值銷售額124億元人民幣的預測,以淨現值估值法給予目標價108元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account